Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HER-2 negative
Cancer:
Gastroesophageal Junction Adenocarcinoma
Drug:
5-fluorouracil
(
Thymidylate synthase inhibitor
) +
oxaliplatin
(
DNA synthesis inhibitor
,
DNA cross linking agent
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
12/23/2020
Excerpt:
Gastroesophageal Junction Adenocarcinoma: Principles of systemic therapy...Preferred regimens…HER2 overexpression negative…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.